Agenus Inc.
AGEN · NASDAQ
Market closed$5.01$0.010000 (+0.20%)After hours $5.02 · +0.20%
Key statistics
Previous close$5.00
Open$4.97
Day high$5.11
Day low$4.79
52-week high$8.70
52-week low$2.71
Market cap208.63M
Volume1.75M
Average volume3.90M
P/E ratio1.99
Forward P/E—
EPS2.52
Dividend yield0.00%
Market context
Why it moved
Agenus shares edged up as the stock consolidated near its Series B warrant exercise price, with investor attention remaining focused on the potential $170 million in proceeds from full warrant exercise that could fund its Phase 3 ROBBIN colon cancer trial, following last week's nearly 50% surge.
What is happening
Recent company-specific developments and publisher coverage.
뉴스와이어 · July 19, 2026Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026Yahoo Finance UK · July 18, 2026Agenus (AGEN) Could Be 83% Undervalued Following Phase 1b Data And FinancingSimply Wall Street · July 17, 2026Agenus (AGEN) Is Up 54.3% After Oversubscribed US$340 Million Private Placement To Fund ROBBIN Trial – Has The Bull Case Changed?Stock Titan · July 17, 2026Agenus cancer combo spans colon cancer and sarcoma at ESMOInvesting.com · July 17, 2026Agenus abstracts on cancer drug combo accepted at ESMO 2026Seeking Alpha · July 15, 2026Agenus Surges 83% On $340 Million Financing: The Road To A 2030 Breakthrough (NASDAQ:AGEN)Sahm · July 15, 2026Agenus (AGEN) Could Be 83% Undervalued On Phase 1b Data And $340 Million RaiseCancerNetwork · July 14, 2026Agenus Discontinues Phase 3 BATTMAN Trial in Metastatic MSS Colorectal Cancer Benzinga · July 14, 2026Why Is Agenus Stock Falling on Tuesday? Benzinga · July 13, 2026Why Is Agenus Stock Gaining Monday? Benzinga · July 13, 2026Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN Mt Newswire · July 13, 2026Agenus Signs Deal to Sell Up to $340 Million Worth of Securities; Shares Up Pre-Bell Benzinga · July 13, 2026Agenus To Raise $85M To Fund Colon Cancer Drug Trial, Financing Could Reach $340M If Warrants Are Exercised Mt Newswire · July 6, 2026Agenus' Potential Colorectal Cancer Combination Shows 21.2-Month Survival Benzinga · July 6, 2026Agenus Presents 3-Yr Landmark Phase 1b Data From Fully Enrolled C-800-01 Cohort Evaluating Botensilimab Plus Balstilimab In Patients With Refractory MSS mCRC Without Active Liver Metastases At ESMO GI 2026 Benzinga · June 25, 2026Agenus To Present 3-Yr Survival Data From Phase 1b C-800-01 Study Of Botensilimab Plus Balstilimab In Patients With Microsatellite Stable mCRC Without Active Liver Metastases At ESMO GI 2026